|
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Treatment of Psoriasis Using Acitretin in HIV-Positive Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical research trials and Treatment of Psoriasis Using Acitretin in HIV-Positive Patients medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Treatment of Psoriasis Using Acitretin in HIV-Positive Patients. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Treatment of Psoriasis Using Acitretin in HIV-Positive Patients clinical trial. Participants oftentimes recieve the finest healthcare available for their Treatment of Psoriasis Using Acitretin in HIV-Positive Patients condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Psoriasis Using Acitretin in HIV-Positive Patients  Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
For Condition: HIV Infections,Psoriasis
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
Details: Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment continues for a total of 20 weeks. Patients are followed every 2 weeks.
Eligibility:
Study Type: Interventional, Treatment, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Any nondermatologic medication. Patients must have: - HIV infection. - Psoriasis involving at least 10 percent of body surface.
Total Enrollment: 30
Location and Contact Information:
Beth Israel Med Ctr
New York City, New York, 10003
United States
Additional Information:
Study ID Numbers: 239A; 65-93(2)
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002143
Other Hiv Infections Studies:
1. To study the use of Humanized CD25 in preventing the relapse of Psoriasis Vulgaris
2. To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris
3. Micellar Paclitaxel to Treat Severe Psoriasis
4. Etanercept (Enbrel®) in Psoriasis - Pediatrics
5. Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
|
|
|
|
|
|
|
|
